Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx Inc.

Ardelyx Inc (($ARDX)) has held its Q1 earnings call. Read on for the main highlights of the call. Ardelyx’s latest earnings call balanced robust co...

Ardelyx Earnings Call Highlights Rapid Growth, Rising Costs

Ardelyx Inc (($ARDX)) has held its Q1 earnings call. Read on for the main highlights of the call. Ardelyx’s latest earnings call painted a broadly ...

Ardelyx Earnings Call: Ibsrela Surge Fuels Bold Targets

Ardelyx ( ($ARDX) ) has provided an update. On April 30, 2026, Ardelyx reported first quarter 2026 product revenue of $93.4 million, up 38% year ov...

Market Cap	$1.50B	P/E Ratio	N/A
52W High	$8.40	52W Low	$3.49
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	14.8%	52W Position	56.3%
Overall Score	45	Value Score	40
Quality Score	50	Technical Score	45

EPS Current Est	$-0.05	EPS Next Est	$0.5
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARDX	$6.26	+2.37%	1.29M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARDX	$6.26	+2.4%	1.29M
3
4
5
6

ARDX

ARDX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Ardelyx Inc. Data in Excel

Get Ardelyx Inc. Data in Excel